MBRX Archived Articles
Moleculin Biotech, Inc. (MBRX): Disrupting the AML Treatment Landscape with Innovative Anthracycline
Published on November 30, 2024
Moleculin Biotech, Inc. (NASDAQ:MBRX): Unlocking the Potential of Annamycin in Acute Myeloid Leukemia
Published on September 24, 2024